ArticleFrontiers in cellular and infection microbiology2025
Carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Comparative clinical outcomes of pandrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections in children.BMC infectious diseases · 2026Article
- Microbiological characterization and clinical outcomes of carbapenem-resistant enterobacterales infections in a paediatric hospital in Mexico.BMC infectious diseases · 2026Observational
- Evaluating eravacycline's efficacy against pediatric carbapenem-resistantMicrobiology spectrum · 2026Article
- Clinical risk factors and genomic characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Risk factors for quinolone-resistantFrontiers in pediatrics · 2026Article
- Widespread Distribution of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2025Review
- Clinical epidemiology and prognostic factors in patients with KPC-producingFrontiers in public health · 2025Article
- COVID-19 pandemic increased ESKAPEEc bloodstream infections and amplified carbapenem resistance in Chinese children: a multicenter surveillance study (2016-2023).Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study assessed epidemiology characteristics, carbapenem-resistance genes, and drug resistance to ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) in children with carbapenem-resistant Methods: A total of 363 non-repetitive CRKP strains were collected from children who underwent two tertiary children's hospital between 1 January 2021 and 30 June 2024 in Chongqing and Kunming in Southwest China. Carbapenem resistance genes and antimicrobial susceptibility were analyzed. Basic clinical characteristics of the patients were obtained from medical records. Results: bla Conclusions: The epidemiological characteristics of Chinese children with CRKP infections, including the resistance genes and the antibiotic resistance of CRKP, exhibited significant variation between the two regions.KPC-KP strains had higher antimicrobial resistance in patients and thus should be given more attention in clinics and infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.